Medical and Pharmaceutical Why are Viridian Therapeutics shares on the rise on Tuesday? Veligrotug’s response rate and metrics suggest competitive, and potentially superior, performance than drug presently on the market Joseph MortonSeptember 10, 2024
Gold Kinross Gold PEA promises high value margins in hot gold market The project promises substantial margins given the current gold price environment Joseph MortonSeptember 10, 2024
Bitcoin Americans lost $5.6B to cryptocurrency fraud in 2023: FBI report Victims of financial fraud involving cryptocurrencies filed nearly 70,000 complaints with the FBI in 2023 Joseph MortonSeptember 9, 2024
Health & Wellness Relay Therapeutics shares soar on positive results for breast cancer treatment Several analysts upgraded their price targets for Relay Therapeutics based on the release Joseph MortonSeptember 9, 2024
Gold Will Federal Reserve interest rate cuts spell new all-time high for gold? Federal Reserve Jerome Powell confirmed that the Fed would cut interest rates on Sept 18 Joseph MortonSeptember 9, 2024
Crypto/Blockchain Telegram CEO calls French charges ‘misguided’ TON's blockchain continues to handle high transaction volumes despite Durov's arrest Joseph MortonSeptember 6, 2024
Mining First Majestic Silver picks up Gatos Silver for $970M deal The acquisition of Gatos Silver boosts First Majestic's annual production expectations to between 30-32 million ounces of silver-equivalent Joseph MortonSeptember 6, 2024
Gold Russia increases gold purchases by 601% to evade sanctions Russia's recent strategy of buying gold in substantial quantities aligns with its broader economic move towards de-dollarization Joseph MortonSeptember 6, 2024
Alternative Energy SaskPower establishes new subsidiary for small modular reactor initiatives The Canadian government has backed the project with up to CAD$74 million for pre-development activities Joseph MortonSeptember 5, 2024
AI and Autonomy Applied Digital shares bolt ahead 65% on big tech cash investment The price movement reflects strong investor optimism about the company's growth potential Joseph MortonSeptember 5, 2024